We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Re-treatment of Patients With Paget's Disease Using Zoledronic Acid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00740129
Recruitment Status : Completed
First Posted : August 22, 2008
Last Update Posted : November 16, 2016
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to demonstrate that patients with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5mg infusion of zoledronic acid.

Condition or disease Intervention/treatment Phase
Paget's Disease of the Bone Drug: Zoledronic Acid Phase 4

Detailed Description:
Uncontrolled study

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Reclast®/Aclasta®, Re-treatment of Relapsed Patients With Paget's Disease of Bone Who Participated in the CZOL446K2304 and CZOL446K2305 Core Registration Studies
Study Start Date : October 2008
Primary Completion Date : March 2011
Study Completion Date : March 2011


Arms and Interventions

Arm Intervention/treatment
1
Open label, single arm treatment study
Drug: Zoledronic Acid
Zoledronic acid 5 mg intravenous infusion once
Other Name: Reclast®/Aclasta®


Outcome Measures

Primary Outcome Measures :
  1. Normalization of total serum alkaline phosphatase within 6 months after a single 5 mg re-treatment dose of zoledronic acid [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Collect information pertaining to relapse diagnosis to define retreatment guidelines for Paget's disease [ Time Frame: 6 months ]
  2. Changes in SAP levels relative to baseline [ Time Frame: 3 & 6 months ]
  3. Collect adverse events profile for re-treated patients [ Time Frame: 6 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written Informed Consent
  • Patients with Paget's disease randomized to the zoledronic acid arm from the CZOL446K2304 and CZOL446K2305 core studies and who were responders by 6 months
  • Confirmed relapse of Paget's disease of bone (i.e. SAP above ULN, bone scan, worsening clinical symptoms)

Exclusion Criteria:

  • A patient previously treated with zoledronic acid who relapsed and was retreated with anti-resorptive bisphosphonate or calcitonin therapy within the last 12 months
  • Bisphosphonate Hypersensitivity
  • Patients with suspected/proven metastases at re-treatment
  • Calculated creatinine clearance <35 mL/min at screening
  • Serum calcium level <2.07 mmol/L at screening
  • Active primary hyperparathyroidism, hyperparathyroidism, hypoparathyroidism or hypothyroidism

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00740129


Locations
Belgium
Novartis Investigative site
Brussels, Belgium
Canada
Novartis Investigative site
Montreal, Canada
Novartis Investigative site
Quebec, Canada
New Zealand
Novartis Investigative site
Aukland, New Zealand
South Africa
Novartis Investigative site
Cape Town, South Africa
Spain
Novartis Investigative site
Barcelona, Spain
Novartis Investigative site
Madrid, Spain
Novartis Investigative site
Salamanca, Spain
Novartis Investigative site
Valencia, Spain
United Kingdom
Novartis Investigative site
Nottingham, United Kingdom
Novartis Investigative site
Oxford, United Kingdom
Sponsors and Collaborators
Novartis Pharmaceuticals
More Information

Additional Information:
Publications:
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00740129     History of Changes
Other Study ID Numbers: CZOL446K2418
First Posted: August 22, 2008    Key Record Dates
Last Update Posted: November 16, 2016
Last Verified: April 2013

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Paget's Disease
Zoledronic acid
Reclast®/Aclasta®
infusion
re-treatment
re-lapse

Additional relevant MeSH terms:
Bone Diseases
Osteitis Deformans
Musculoskeletal Diseases
Zoledronic acid
Diphosphonates
Bone Density Conservation Agents
Physiological Effects of Drugs